AI-powered evaluation using the Model Context Optimization BS Detection Framework, based solely on publicly available website content.
Based on 587 businesses audited.
Medical Devices, Pharma & Biotech BS: IMFINZI (durvalumab) (imfinzi.com)
This is a high-substance, low-BS pharmaceutical site that prioritizes regulatory compliance and clinical specificity over marketing fluff. The low score reflects a site that backs almost every indication claim with specific treatment protocols and FDA-approved contexts. The minor points are deducted for technical schema absences and repetitive heading structures rather than deceptive content.
Implement Product and Organization schema to formalize authority and link to clinical study identifiers. Add specific ClinicalTrials.gov (NCT) numbers next to the ‘See the clinical trial results’ prompts to strengthen the proof path. Consolidate repetitive H2 headings to improve structural coherence and ensure each heading provides unique value. Add a clear adverse event reporting mechanism or link to a pharmacovigilance portal in a more prominent position than the standard footer ISI.
The information density is exceptionally high, with body text dominated by specific medical terminology and clinical data. For example, the GC/GEJC page specifies the exact chemotherapy regimen (Fluorouracil, leucovorin, oxaliplatin, and docetaxel) rather than using generic terms. Fluff is nearly non-existent in the headings, except for the H1 on the gastric cancer page which uses ‘leading the way,’ a minor power word infraction. The specificity of cancer stages (Stage 2A-3B, Extensive-stage SCLC) ensures the substance far outweighs marketing air.
If your content is buried under div based wrappers, AI will treat it as noise instead of meaning. Check your Machine Readability Index with a free one page structural interpretation.
There is no detectable semantic drift between the homepage and sub-pages. The homepage H1 ‘IMFINZI treats multiple types of cancer’ is systematically supported by dedicated sub-pages for NSCLC, SCLC, and Gastric Cancer, each providing deeper clinical detail. The messaging remains consistent throughout, moving from high-level indications to granular stage-based treatment options without conflicting claims.
Our Authority as a Service model transforms raw diagnostic data into high stakes results. Start your Clinical Strategic Diagnosis for 1 Euro to secure the strategic fixes required for growth.
Trust theatre is absent; the site records a review_count of 0 and a trust_theatre_flag of false, which is appropriate for a regulated pharmaceutical product. The site relies on clinical trial results and FDA approval status rather than unverified customer testimonials. While the text references ‘clinical trial results,’ the forensic data does not show direct citations or NCT numbers in the body text, representing a minor proof path gap.
The proof density is high, supported by the mention of clinical trial stages and specific chemotherapy combinations. The site provides specific instructions for healthcare provider consultation and lists detailed side effects, which serves as a form of regulatory proof. The ratio of substantiated clinical claims to vague marketing assertions is approximately 9:1.
For a high volume editorial domain example, open the Search Engine Journal Semantic HTML audit. View the SEJ Semantic HTML Audit to see how template drift and structural noise impact AI chunking.
The site avoids most value proposition clichés, though it does use industry-standard jargon like ‘FDA-approved immunotherapy’ and ‘pioneering advancements.’ The content is highly unique to the specific molecule (durvalumab) and cannot be easily swapped with a competitor due to the specific indications listed. The only boilerplate elements are the ‘Important Safety Information’ (ISI) blocks, which are regulatory requirements rather than marketing templates.
A significant technical gap exists in the absence of structured data (schema_json is null), which fails to formally define the Brand or Product for search engines. While the brand is a clear authority in the medical space, the technical implementation lacks Person schema for clinical experts or Organization schema for AstraZeneca. Additionally, the crawl reveals repetitive H2 headings (‘What is IMFINZI?’ appearing multiple times), suggesting minor structural inefficiency.
The performance claims made, such as being the ‘#1 prescribed immunotherapy,’ are supported by specific time-bound footnotes (Jan 2019 to Jan 2025). The marketing tone is subdued by the heavy inclusion of safety warnings and contraindications, which balances promotional language with medical reality. There are no bold performance claims that lack an anchored clinical or regulatory context.
Medical Devices, Pharma & Biotech BS: IMFINZI (durvalumab) (imfinzi.com)
The website perfectly aligns with the Pharma and Biotech industry, focusing on FDA-approved immunotherapy indications and regulatory-mandated safety information. The content is heavily clinical, discussing specific cancer stages like LS-SCLC and treatment regimens such as FLOT and chemoradiation therapy (CRT).
Before embeddings, before entities, before retrieval — the crawler must reach the text. Open the Crawlability & Indexation Guide to learn how access failures erase meaning long before interpretation begins.
“The score of 14 is driven primarily by minor technical gaps in Identity and Authority (missing schema) and structural repetition in Information Density. The core messaging and clinical claims are highly substantiated, resulting in near-zero scores for Semantic Drift and Commodity Fingerprint.”